Inhaled treprostinil associated with 95.6 ml smaller FVC decline than placebo in IPF
Inhaled treprostinil slows lung function decline in pulmonary fibrosis
This Phase 3 randomized controlled trial of 593 patients with idiopathic pulmonary fibrosis found that inhaled treprostinil resulted in a 95…
A new inhaled treatment may slow the loss of lung capacity and reduce clinical worsening for people with pulmonary fibrosis.
Inhaled treprostinil reduces FVC decline by 130.1 ml and clinical worsening in IPF
Trial shows inhaled treprostinil slows lung function decline in IPF
This Phase 3 randomized trial of 598 patients with idiopathic pulmonary fibrosis found that inhaled treprostinil significantly slowed the de…
A new trial shows that inhaled treprostinil may slow the loss of lung function and reduce clinical worsening for people with IPF.
Inhaled treprostinil is the only approved therapy with randomized evidence for pulmonary hypertension associated with interstitial lung disease
Inhaled treprostinil shows promise for specific types of lung disease
This narrative review examines pharmacological management of pulmonary hypertension associated with interstitial lung disease (PH-ILD) and i…
New research clarifies which treatments actually work for patients facing both pulmonary hypertension and scarring of the lungs.
Parenteral Treprostinil Shows Efficacy in Pediatric PAH, Meta-Analysis Confirms
Can parenteral treprostinil help kids with pulmonary arterial hypertension?
Meta-analysis of 143 patients shows parenteral treprostinil benefits in pediatric PAH. Data supports efficacy and safety.
Parenteral treprostinil shows clear treatment benefits and safety for children with pulmonary arterial hypertension, offering hope for famil…